Breaking News

Dr. Reddy’s, TR-Pharm in Biosimilars Alliance

March 14, 2016

To develop and commercialize three biosimilars in Turkey

Dr. Reddy’s and TR-Pharm have entered a strategic collaboration agreement for three biosimilars, under which three products will be registered and subsequently commercialized by TR-Pharm in Turkey. TR-Pharm will also manufacture the drug substance and drug product upon completion of its facility investment.
TR-Pharm has begun working on the technology transfer. This collaboration will be an important part of TR-Pharm’s ongoing biologic product development and manufacturing business in the region. The partnership also allows Dr. Reddy’s to expand the global footprint of its biosimilar business.
Mehmet Göker, general manager of TR-Pharm, said, “Biosimilars are a key component of our investment strategy in Turkey to establish biotechnological API production for national use and regional exports. This agreement will not only enable more affordable medication but also support our research and development initiatives by building expertise within the country. We are pleased to have already started laying out the groundwork for manufacturing with Dr. Reddy’s for high quality biosimilar products.”
M V Ramana, executive vice president and head Branded Markets at Dr. Reddy’s, said, “Turkey is a key emerging market and we are pleased to partner with TR-Pharm to ensure that patients in the region get access to our portfolio of high quality biosimilar products. Dr. Reddy’s remains committed to providing access to affordable and innovative drugs to populations around the world, and this partnership will make this happen in Turkey.”

Related Contract Manufacturing:

blog comments powered by Disqus
  • Biosimilars Outsourcing and Capacity

    Biosimilars Outsourcing and Capacity

    Ronald A. Rader and Eric S. Langer, BioPlan Associates||May 5, 2016
    CMOs to play important but uncertain role in biosimilars manufacturing

  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.